Scandinavian Journal of Haematology · 1986 · 48 citations · 6 references
Life SciencesHematologyImmunologyAutoimmunityClinical ImmunologyImmunopathologyAutoimmune Disease PathogenesisAutoimmune DiseasesAutoimmune Hematologic DiseaseHematologic ToxicityImmune-related Adverse EventsInterferon-based TherapyAutoimmune ThrombocytopeniaImmune-mediated ThrombocytopeniaInterferon Alfa TherapyInterferon-mediated Pathology
A patient with renal cell carcinoma developed reversible autoimmune thrombocytopenia while receiving leukocyte interferon (IFN) and subsequently fibroblast IFN. Bone marrow biopsies and elevated platelet-associated IgG were suggestive of immune thrombocytopenia. The patient's history of exposure to IFN and exclusion of other causes are most consistent with drug-induced immune thrombocytopenia. Rechallenge with acetaminophen, the only other drug the patient was receiving concurrently, failed to induce thrombocytopenia. With IFN alpha, acute thrombocytopenia resolved within 48 h, whereas after IFN beta it was 5 wk before platelet counts returned to normal. PaIgG, however, remained elevated for up to 30 wk. Sensitive in vitro tests failed to confirm drug-dependent binding of IgG to the patient's platelets. It is suggested that this patient developed interferon-induced autoimmune thrombocytopenia.
6
The biology of the interferon system 1984
Alfons Billiau · Trends in biotechnology · 1985 · 431 citations
Immune thrombocytopenia in lymphoproliferative diseases
BR Kaden, WF Rosse, TW Hauch · Blood · 1979 · 112 citations · Full text
Medicine, Hematology, Immunology +12
T A McPherson, Yadi Tan · JNCI Journal of the National Cancer Institute · 1980 · 26 citations
Pharmacy, Oncology, Pharmacology +16